Allison Transmission reported a 121% year-over-year increase in Q3 net sales to $1.534 billion, driven by the acquisition of Allison Off-Highway and strong demand in key markets. The company posted net income of $191 million and adjusted EBITDA of $400 million, with adjusted diluted EPS up 59% year-over-year. Strong cash flow enabled significant debt repayment and ongoing shareholder returns through dividends and stock buybacks. Allison raised its full-year 2026 guidance, expecting consolidated net sales between $5.975 billion and $6.075 billion, and net income between $645 million and $685 million, reflecting confidence in market demand and operational execution.
Allison Transmission's third quarter 2026 results provide context as of Nov 03, 2026 04:01 WIB. For readers following Industrials-sector US stocks on Pluang, here is the market snapshot: out of 135 priced stocks, 66 rose and 69 fell. Notable movers include FCEL at USD 11.22 with a 7.88% decline and 98% sell order activity, LUNR at USD 9.85 down 7.69% with 100% sell order activity, and NAT at USD 7.32 down 7.46%.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NEAR governance approved a plan to reduce the maximum annual issuance of the NEAR token from 2.5% to 1.6%. This change aims to slow the rate at which new tokens enter circulation, potentially impacting staking rewards by lowering them. The plan inclu...
